Summary
Danaher Corporation's 2013 10-K filing highlights a diversified company with five key segments: Test & Measurement, Environmental, Life Sciences & Diagnostics, Dental, and Industrial Technologies. The company's strategy is centered on driving shareholder value through sales growth exceeding market growth, achieving upper-quartile financial performance, and generating strong cash flow, all underpinned by the Danaher Business System (DBS). Financially, the company demonstrated revenue growth driven by both existing businesses and acquisitions, with approximately 58% of sales generated internationally. While facing some market challenges and currency headwinds, Danaher continued to invest in R&D, with expenditures totaling $1.25 billion. The company also actively managed its capital structure, reducing debt and approving a new share repurchase program. Key financial indicators such as sales, operating profit, and net earnings showed an upward trend compared to the previous year, reflecting the company's operational execution and strategic acquisitions.
Financial Highlights
54 data points| Revenue | $18.28B |
| Cost of Revenue | $8.94B |
| Gross Profit | $9.34B |
| R&D Expenses | $1.10B |
| SG&A Expenses | $5.12B |
| Operating Income | $3.12B |
| Interest Expense | $141.20M |
| Net Income | $2.69B |
| EPS (Basic) | $3.87 |
| EPS (Diluted) | $3.80 |
| Shares Outstanding (Basic) | 696.00M |
| Shares Outstanding (Diluted) | 711.00M |
Key Highlights
- 1Danaher operates across five diverse segments: Test & Measurement, Environmental, Life Sciences & Diagnostics, Dental, and Industrial Technologies, indicating a broad market reach.
- 2The company's core strategy revolves around the Danaher Business System (DBS) to drive continuous improvement in quality, delivery, cost, and innovation, aiming for superior financial performance and cash flow generation.
- 3In 2013, Danaher reported total sales of $19.118 billion, a 4.5% increase from the prior year, with a significant portion (58%) of sales coming from international markets.
- 4The Life Sciences & Diagnostics segment was the largest contributor to revenue ($6.856 billion), followed by Test & Measurement ($3.417 billion) and Industrial Technologies ($3.432 billion).
- 5Research and development expenses increased to $1.25 billion in 2013, signaling continued investment in innovation and product development across its segments.
- 6The company demonstrated a healthy debt reduction, with total debt decreasing from $5.343 billion in 2012 to $3.499 billion in 2013, and maintained a strong liquidity position with $3.1 billion in cash and cash equivalents as of year-end 2013.
- 7Danaher completed 14 acquisitions in 2013 for a total consideration of $957 million, alongside significant divestitures like the sale of its investment in the Apex Tool Group, demonstrating active portfolio management.